Combination with HSP90 inhibitors is evaluated as an effective strategy to overcome the resistance of JAK2 inhibitors in fibrotic diseases and myeloproliferative neoplasms (Zhang et al., 2017). This evidence concerns the gene HSP90AB1 and myeloproliferative disorder.